Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ActHIB + DPT-TAKEDA
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ActHIB + DPT-TAKEDA is a combination vaccine consisting of two components: - **ActHIB** is a lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine. - **DPT-TAKEDA** refers to the Japanese commercial formulation of diphtheria and tetanus toxoids combined with an acellular pertussis component developed by Takeda. This combination is used to immunize children against four serious bacterial diseases: diphtheria, tetanus, pertussis (whooping cough), and invasive disease caused by Haemophilus influenzae type b. The mechanism of action involves stimulating the immune system to produce antibodies against each pathogen's key antigens—diphtheria toxin, tetanus toxin, Bordetella pertussis antigens, and Hib polysaccharide-protein conjugate—thereby providing protective immunity[3][5][6].
- Other names
- Haemophilus influenzae type b conjugate vaccine + diphtheria and tetanus toxoids and acellular pertussis vaccine (Takeda)Hib-DTPa (Takeda)
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on ActHIB + DPT-TAKEDA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ActHIB + DPT-TAKEDA.